 In a study in which multiple, subcutaneous doses of both 25 and 50 µg/kg were administered to cancer patients receiving chemotherapy, Neumega did not accumulate and clearance of Neumega was not altered following multiple doses.Pediatric cancer patients treated with aggressive chemotherapy showed similar pharmakinetic characteristics.In humans treated with Oprelvekin on a daily base a twofold increase in fibrinogen levels occurred.